sodelglitazar
Small moleculeexperimental
Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline. While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors. — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00196989)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Peroxisome proliferator-activated receptor agonist
Ph2 study terminated due to safety concerns
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3F)nc2C)ccc1OC(C)(C)C(=O)O- Mol. weight
- 499.55 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSodelglitazar ↗
- ChEMBLCHEMBL2104984 ↗
Also known as
- gw677954
- gw677954
- gw677954
- sodelglitazar
- sodelglitazar
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00437164 | Phase 2 | Sep 1, 2006 | GlaxoSmithKline |
| NCT00264667 | Phase 2 | Dec 1, 2005 | GlaxoSmithKline |
| NCT00196989 | Phase 2 | Sep 1, 2005 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 1 | 2005 |
1 organizations
Page 1 / 1